10-Q: Qualigen Therapeutics Faces Going Concern Doubt

Qualigen Therapeutics reports significant losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern, despite recent capital raises.

Summary

• Qualigen Therapeutics, an early-clinical-stage therapeutics company, reported a net loss of $4,331,588 for the six months ended June 30, 2025, compared to $3,609,309 for the same period in 2024.
• Cash and cash equivalents decreased significantly to $331,601 as of June 30, 2025, from $1,174,608 at December 31, 2024.
• The company used $2,687,507 in cash from operating activities for the six months ended June 30, 2025.
• An accumulated deficit of $127.4 million was reported as of June 30, 2025.
• General and administrative expenses increased by 88% to $3.9 million for the six months ended June 30, 2025, primarily due to a $1.5 million increase in investor relation fees.
• Research and development expenses decreased by 95% to $51,000 for the six months ended June 30, 2025, as development of therapeutic products was slowed due to financial constraints.
• A credit loss expense of $828,000 was estimated for short-term notes receivable from Marizyme as of June 30, 2025, due to the uncertain financial condition of the debtor.
• The company raised $3,640,000 from nine investors in short-term borrowings from January to July 2025 and an additional $4,258,000 from a private placement in July 2025.
• Material weaknesses in internal controls were identified, including insufficient accounting personnel, lack of effective IT General Controls, and absence of formalized documentation.
• A lawsuit from LifeSci Capital LLC for $503,483 for alleged unpaid placement agent fees is in the discovery phase, with the company vigorously defending the claim.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the explicit 'substantial doubt about the company's ability to continue as a going concern,' significant cash burn, increasing losses, and the necessity to slow down core R&D activities. While capital was raised, it appears to be a stop-gap measure, and the terms of some recent financings (e.g., high penalties on promissory notes, OID on convertible debt) suggest a distressed financial position. The identified material weaknesses in internal controls further compound the negative outlook.

Positives

• Successfully closed a private placement transaction in July 2025, raising $4,258,000, which is expected to provide liquidity through calendar year end.
• Secured $3,640,000 in short-term borrowings from nine investors from January to July 2025.
• Management has implemented dramatic expense controls to stem the rate of losses, particularly in research and development.
• Interest income increased significantly to $0.3 million for the six months ended June 30, 2025, primarily from Marizyme notes receivable.

Negatives

• Reported a net loss of $4,331,588 for the six months ended June 30, 2025, an increase from $3,609,309 in the prior year period.
• Cash and cash equivalents declined sharply to $331,601 as of June 30, 2025, from $1,174,608 at December 31, 2024.
• Accumulated deficit reached $127.4 million, indicating a history of significant losses.
• Used $2.7 million in cash from operating activities for the six months ended June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern.
• Research and development activities have been significantly slowed down in 2025 due to financial constraints.
• Incurred a credit loss expense of $828,000 on short-term notes receivable from Marizyme.
• General and administrative expenses increased by $1.8 million, or 88%, for the six months ended June 30, 2025, largely due to investor relation fees.
• Current liabilities total $5,614,956 as of June 30, 2025, exceeding current assets of $3,960,673.

Risks

• Ability to procure sufficient working capital to continue and complete the development, testing, and launch of prospective drug products.
• Ability to successfully develop any drugs and progress drug candidates through preclinical and clinical development.
• Ability to obtain requisite regulatory approvals for clinical trials and complete them according to projected timelines.
• Likelihood that future clinical trial data will be favorable or confirm improvements over other products, or lack negative impacts.
• Ability to successfully commercialize any drugs.
• Likelihood that patents will issue on in-licensed patent applications and ability to protect intellectual property.
• Ability to compete in the biotechnology industry.
• Risks associated with global economic conditions, including inflation and ongoing wars in Ukraine and Israel, which could impact operations and financial results.
• Potential for dilution of common stockholders' ownership interests if additional capital is raised through equity or convertible debt securities.
• Debt financing, if available, may involve agreements with covenants limiting specific actions.
• Reliance on third-party funding, commercialization, marketing, and distribution arrangements may require relinquishing valuable rights.
• Uncertainty regarding the financial condition of Marizyme, Inc. and the recoverability of short-term notes receivable.
• Material weaknesses in internal control over financial reporting due to insufficient accounting personnel, lack of effective IT General Controls, and absence of formalized documentation.
• Ongoing litigation with LifeSci Capital LLC for alleged unpaid fees, with an uncertain outcome.

Future Outlook

The company expects to continue incurring net losses and negative cash flow from operations, which will challenge its liquidity. Management and the board are strategically reviewing plans to advance the therapeutics pipeline and will ramp up development when properly funded through capital markets or strategic partnerships. The company anticipates that recent capital raises will provide liquidity through calendar year end. The company is evaluating the impact of the recently passed One Big Beautiful Bill (OBBB) on corporate taxation but does not expect a material impact on results of operations.

Management Comments

• "We expect to continue to have net losses and negative cash flow from operations, which will challenge our liquidity."
• "These factors raise substantial doubt regarding our ability to continue as a going concern for the one-year period following the date that the financial statements in this Quarterly Report were issued."
• "To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders."
• "Given our financial situation, the company slowed the development of the aforementioned therapeutic products beginning in the second quarter of 2024."
• "We have also implemented dramatic expense controls in an effort to stem the rate of losses."
• "Management and the board are strategically reviewing plans on how to best advance our therapeutics pipeline, and will ramp up development when properly funded through either capital markets or strategic partnerships."
• "The Company deemed this expense [IR Agency LLC fees] necessary to raise additional funding which would provide liquidity to the Company for business operations. This expense is not anticipated to be recurring in future periods."

Industry Context

Qualigen Therapeutics operates in the highly capital-intensive and high-risk early-clinical-stage biotechnology sector, focused on cancer therapeutics. It is typical for companies in this stage to experience significant losses and negative cash flow as they invest heavily in research and development without commercialized products. The company's current financial struggles, including the need for continuous capital raises and the slowing of R&D, are indicative of the challenges faced by many small biotech firms that have not yet achieved clinical or commercial breakthroughs. The reliance on dilutive financing and the substantial doubt about going concern are common themes for companies at this stage that are not yet self-sustaining.

Comparison to Industry Standards

• Qualigen's accumulated deficit of $127.4 million and recurring net losses are typical for early-stage biotechnology companies that are pre-revenue and heavily invested in R&D, similar to many small-cap oncology biotechs that require significant capital to advance drug candidates through clinical trials.
• The substantial reduction in R&D expenses (95% decrease) and the slowing of development for QN-302 and Pan-RAS programs are concerning, as they indicate a severe capital constraint that is not typical for companies actively progressing promising drug candidates, unlike well-funded peers who maintain consistent R&D investment.
• The company's cash position of $331,601 is critically low compared to industry benchmarks for clinical-stage biotechs, which typically aim for at least 12-18 months of cash runway to fund operations and clinical trials without immediate financing pressure.
• The frequent reliance on convertible debt and promissory notes with high interest rates (e.g., 18% on Marizyme Notes) and significant discounts/penalties (e.g., 20% OID on 2025 Convertible Note, 30% penalty on promissory notes) suggests a distressed financing environment, contrasting with more established biotechs that can secure less dilutive or lower-cost capital.
• The identified material weaknesses in internal controls (insufficient accounting personnel, ITGC issues) are below industry best practices for publicly traded companies, which prioritize robust financial reporting and compliance infrastructure.

Corporate Governance

Legal Proceedings

• On January 29, 2025, the company was named as a defendant in an action brought by LifeSci Capital LLC in the U.S. District Court for the Southern District of New York, alleging failure to pay $503,483 in connection with common stock offerings. The company denies the allegations and is vigorously defending the lawsuit, not believing a loss is probable or reasonably estimable at this time.

Related Party Transactions

• The company issued an 8% Senior Convertible Debenture to Alpha Capital Anstalt on December 22, 2022, with a principal amount of $3,300,000. The remaining principal balance was converted into 103,876 shares of common stock during 2024.
• On February 27, 2024, the company issued an 8% Convertible Debenture to Alpha Capital Anstalt for $550,000 principal. The remaining principal and accrued interest were repaid in cash on November 20, 2024.
• On April 12, 2024, the company issued an 8% Convertible Debenture with a principal amount of $1,100,000 to Yi Hua Chen (Alpha assigned the option to Chen). This debenture was settled by issuing 1,154 shares of Series A-2 Preferred Stock on November 18, 2024.
• On April 28, 2025, the company entered into a Secured Convertible Note with Alpha Capital Anstalt for $264,000 principal.
• Warrants were issued to Alpha Capital Anstalt in conjunction with debentures, with exercise prices adjusted due to down-round provisions.
• Warrants were issued to Yi Hua Chen in connection with the convertible debenture, with exercise prices adjusted due to down-round provisions.

Stakeholder Impact

• **Shareholders:** Significant dilution is expected from ongoing and future capital raises through equity and convertible debt. The 'substantial doubt about going concern' poses a severe risk to investment value. The 1-for-50 reverse stock split in November 2024 indicates efforts to maintain Nasdaq listing, but the underlying financial weakness persists.
• **Employees:** Payroll expenses decreased by $0.7 million for the six months ended June 30, 2025, suggesting potential workforce reductions or cost-cutting measures impacting employees. The identified material weaknesses in internal controls due to 'insufficient number of accounting personnel' also point to understaffing.
• **Customers/Partners:** The slowing of research and development activities for QN-302 and Pan-RAS programs could delay or jeopardize the availability of future therapeutic products. The credit loss expense on Marizyme notes indicates potential financial strain on a key co-development partner, which could impact the DuraGraft royalty stream.
• **Creditors:** The company's weak financial position and 'substantial doubt about going concern' increase credit risk. The issuance of promissory notes with high penalties and premiums suggests a high cost of debt and potential difficulty in timely repayments.

Next Steps

• Strategically review plans on how to best advance the therapeutics pipeline.
• Ramp up development of therapeutic products when properly funded through capital markets or strategic partnerships.
• Continue to monitor relevant events and conditions and update assumptions and allowance for credit losses on short-term notes receivable.
• Remediate identified material weaknesses in internal controls, contingent on obtaining additional funding to strengthen the accounting department.
• Continue to vigorously defend the lawsuit brought by LifeSci Capital LLC.

Key Dates

Recommendation

The filing presents a dire financial situation with 'substantial doubt about the company's ability to continue as a going concern.' The company is experiencing significant and increasing net losses, a critically low cash balance, and negative cash flow from operations. While recent capital raises provide short-term liquidity, they are highly dilutive and come with unfavorable terms (e.g., high interest, OID, penalties). The slowing of core R&D programs, which are essential for a clinical-stage biotech, indicates a severe lack of funding for its primary business. Furthermore, identified material weaknesses in internal controls raise concerns about financial reporting integrity. Given the severe liquidity issues, ongoing losses, operational slowdown, and high risk of further dilution or potential bankruptcy, a seasoned investor would likely recommend a strong sell.

Keywords

Biotechnology, Oncology, Cancer therapeutics, Clinical stage, QN-302, Pan-RAS, SEC filing, 10-Q, Financial results, Liquidity, Going concern, Capital raise, Convertible debt, Warrants, Research and development, Corporate governance, Risk factors